Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Insulet ( (PODD) ) just unveiled an update.
On January 29, 2026, Insulet Corporation and NXP USA, Inc. entered into a 2026 Addendum, effective January 1, 2026, that extends the term of their existing 2017 purchase agreement and revises conditions related to pricing, product volume, and order flexibility. The amended arrangement is intended to secure continued supply and more adaptable commercial terms, which may enhance Insulet’s operational stability and cost management in its supply chain and could strengthen its positioning in securing critical components for its medical device production.
The most recent analyst rating on (PODD) stock is a Hold with a $280.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.
Spark’s Take on PODD Stock
According to Spark, TipRanks’ AI Analyst, PODD is a Outperform.
Insulet’s strong financial performance and positive earnings call highlight its growth potential, particularly in international markets. However, technical analysis indicates bearish trends, and the high P/E ratio suggests overvaluation. Recent strategic corporate appointments are positive but do not offset the technical and valuation concerns.
To see Spark’s full report on PODD stock, click here.
More about Insulet
Insulet Corporation operates in the medical technology industry, focusing on diabetes management devices and related components. The company relies on suppliers such as NXP USA, Inc. for key products under long-term purchase agreements that support its manufacturing and supply chain needs.
Average Trading Volume: 798,064
Technical Sentiment Signal: Hold
Current Market Cap: $18B
Find detailed analytics on PODD stock on TipRanks’ Stock Analysis page.